跳转至内容
Merck
CN
  • Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages.

Exome sequencing of bilateral testicular germ cell tumors suggests independent development lineages.

Neoplasia (New York, N.Y.) (2015-03-10)
Sigmund Brabrand, Bjarne Johannessen, Ulrika Axcrona, Sigrid M Kraggerud, Kaja G Berg, Anne C Bakken, Jarle Bruun, Sophie D Fosså, Ragnhild A Lothe, Gustav Lehne, Rolf I Skotheim
摘要

Intratubular germ cell neoplasia, the precursor of testicular germ cell tumors (TGCTs), is hypothesized to arise during embryogenesis from developmentally arrested primordial germ cells (PGCs) or gonocytes. In early embryonal life, the PGCs migrate from the yolk sac to the dorsal body wall where the cell population separates before colonizing the genital ridges. However, whether the malignant transformation takes place before or after this separation is controversial. We have explored the somatic exome-wide mutational spectra of bilateral TGCT to provide novel insight into the in utero critical time frame of malignant transformation and TGCT pathogenesis. Exome sequencing was performed in five patients with bilateral TGCT (eight tumors), of these three patients in whom both tumors were available (six tumors) and two patients each with only one available tumor (two tumors). Selected loci were explored by Sanger sequencing in 71 patients with bilateral TGCT. From the exome-wide mutational spectra, no identical mutations in any of the three bilateral tumor pairs were identified. Exome sequencing of all eight tumors revealed 87 somatic non-synonymous mutations (median 10 per tumor; range 5-21), some in already known cancer genes such as CIITA, NEB, platelet-derived growth factor receptor α (PDGFRA), and WHSC1. SUPT6H was found recurrently mutated in two tumors. We suggest independent development lineages of bilateral TGCT. Thus, malignant transformation into intratubular germ cell neoplasia is likely to occur after the migration of PGCs. We reveal possible drivers of TGCT pathogenesis, such as mutated PDGFRA, potentially with therapeutic implications for TGCT patients.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
氯仿, contains 100-200 ppm amylenes as stabilizer, ≥99.5%
Sigma-Aldrich
氯仿, contains ethanol as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
氯化镁 溶液, Molecular Biology, 1.00 M±0.01 M
Sigma-Aldrich
氯化镁, ≥98%
Sigma-Aldrich
苯酚 溶液, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, Molecular Biology
Sigma-Aldrich
氯仿, contains amylenes as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
苯酚, puriss., ≥99.5% (GC), meets analytical specification of Ph. Eur., BP, USP, crystalline (detached)
Sigma-Aldrich
氯化镁, powder, <200 μm
Sigma-Aldrich
氯仿, ACS spectrophotometric grade, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
氯仿, anhydrous, ≥99%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
氯仿, anhydrous, contains amylenes as stabilizer, ≥99%
Sigma-Aldrich
苯酚 溶液, Saturated with 0.01 M citrate buffer, pH 4.3 ± 0.2, BioReagent, Molecular Biology
Sigma-Aldrich
苯酚, ≥99%
Sigma-Aldrich
氯化镁 溶液, BioUltra, Molecular Biology, 2 M in H2O
Sigma-Aldrich
液状苯酚, ≥89.0%
Sigma-Aldrich
苯酚, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Supelco
苯酚, Pharmaceutical Secondary Standard; Certified Reference Material
USP
苯酚, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
氯化镁 溶液, BioUltra, Molecular Biology, ~1 M in H2O
Sigma-Aldrich
苯酚, Molecular Biology
Sigma-Aldrich
氯化镁, suitable for insect cell culture, BioReagent, ≥97.0%
Sigma-Aldrich
氯化镁 溶液, PCR Reagent, 25 mM MgCI2 solution for PCR
Sigma-Aldrich
苯酚, BioXtra, ≥99.5% (GC)
Supelco
苯酚 溶液, certified reference material, 500 μg/mL in methanol
Sigma-Aldrich
苯酚, ACS reagent, ≥99.0%
Sigma-Aldrich
苯酚, unstabilized, ReagentPlus®, ≥99%
Supelco
氯仿, analytical standard
Sigma-Aldrich
苯酚, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
Supelco
苯酚 溶液, 5000 μg/mL in methanol, certified reference material
Sigma-Aldrich
苯酚, unstabilized, purified by redistillation, ≥99%